Patients with autoimmune hepatitis (AIH) initially respond to corticosteroids but often relapse after treatment is withdrawn. BALB/c mice with disruption of programmed cell death-1 (PD-1 -/mice) given thymectomies 3 days after birth develop a dysregulated immne system, greatly reduced Foxp3 + regulatory T cells, and undergo fulminant hepatic failure resembling acute-onset AIH in humans. We examined whether splenectomy overcomes corticosteroid insufficiency and reduces the severity of AIH in these mice. We also developed a mouse model of chronic AIH to investigate the effects of splenectomy. METHODS: After thymectomy, BALB/c-PD-1 -/mice were given dexamethasone before or after induction of AIH; splenectomies were performed in mice that had and had not been given dexamethasone. Neonatal C57BL/6-PD-1 -/mice were given thymectomies to create a model of chronic AIH.
Introduction
Corticosteroid administration is the first-line therapy for patients with autoimmune hepatitis (AIH). The majority initially respond well to corticosteroids, alone or in combination with azathioprine. [1] [2] [3] [4] After initial remission, maintenance therapy is continued for years. However, long-term treatment is discontinued in 13% of AIH patients because of drug-related side effects. 5, 6 Half of AIH patients with remission relapse within 6 months after corticosteroid withdrawal, and multiple relapses are associated with a poor prognosis. 7, 8 Even when liver inflammation disappears completely, 13% of those patients eventually relapse. 9 In addition to the difficulty in sustaining remission, a recent study showed that the long-term mortality of AIH patients due to liver disease is greater than that of the general population. 10 Notably, in Europe and the United States, AIH patients account for 4% of liver transplants. 4 To find clues to overcoming the therapeutic insufficiency of corticosteroids, preclinical animal models for detail examination are needed.
AIH is characterized by mononuclear-cell infiltration in the liver and elevated gammaglobulins as well as by the production of a variety of characteristic autoantibodies (autoAbs), including anti-nuclear antibodies (ANA). [1] [2] [3] Liver-infiltrating T cells are considered the primary disease mediators of inflammatory liver damage, and circulating autoAbs are diagnostic hallmarks. [1] [2] [3] However, in AIH patients, clinical manifestations are varied, ranging from non-symptomatic mild chronic hepatitis to fulminant hepatic failure. [1] [2] [3] It is unclear whether the varied clinical manifestations of AIH result from the same immune dysregulation.
Recently, we developed the first mouse model of spontaneous AIH. 11, 12 In programmed cell death 1-deficient (PD-1 -/-) mice on the BALB/c background with neonatal thymectomy (NTx) three days after birth, immune dysregulation by a concurrent loss of naturally arising Foxp3 + regulatory T cells (Tregs) and PD-1-mediated signaling induced fatal AIH resembling acute-onset AIH, presenting in humans as fulminant hepatic failure. 11 The development of fatal AIH was initiated at two weeks of age, and extensive destruction of the liver parenchyma resulted in most mice dying by four weeks. Fatal AIH in BALB/c-NTx-PD-1 -/mice was characterized by CD4 + and CD8 + T-cell infiltration with massive lobular necrosis in the liver, hyper-gammaglobulinemia, and production of ANA. 11, 12 In BALB/c-NTx-PD-1 -/mice, fatal AIH was initiated at two weeks by splenic follicular helper T (T FH ) cells, powerfully assisting B cells in forming germinal centers (GCs). 13 In addition, these T FH cells in the spleen directly migrated into the liver via the CCR6-CCL20 axis, triggering the induction of AIH. 12 In the present study, using our mouse model of fatal AIH, we examined the effects of administering dexamethasone (DEX) versus splenectomy on the development or progression of AIH. In addition, we developed a new model of chronic AIH.
NTx-PD-1 -/mice on the different genetic background C57BL/6 developed chronic hepatitis with fibrosis, hyper-gammaglobulinemia, and the production of ANA, allowing us to examine the effects of administering DEX versus splenectomy.
However, the development of mouse models of chronic hepatitis similar to the human disease remained an important challenge.
Materials and Methods
All protocols for mice, administration of DEX in vivo, histological and immunohistological analysis, flow cytometry analysis, isolation of lymphocytes, ELISA, adoptive transfer, and histological activity index (HAI) scores, 14 are detailed in Supplementary Methods.
Statistical analysis
The data are presented as the mean values ± SD. Statistical analysis was performed by Student's t-test for unpaired data to compare the values between the two groups, and variance was analyzed with the Tukey-Kramer test for multiple comparisons. Survival rates were estimated by the Kaplan-Meier method and compared with the log-rank test. P-values below .05 were considered significant.
Results

DEX prevents the development of fatal AIH in BALB/c-NTx-PD-1 -/mice
First, to determine whether corticosteroid treatment prevents AIH in BALB/c-NTx-PD-1 -/mice, these mice at one day after thymectomy were intraperitoneally injected every other day with DEX diluted in PBS or with PBS alone ( Figure 1A ). After 13 injections, mice at four weeks of age showed that DEX injections suppressed severe infiltration of mononuclear cells as well as massive destruction of the liver parenchyma with decreased serum concentrations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), resulting in a significantly higher survival rate compared with control PBS injections ( Figure 1A , B and Supplementary Figure 1A) .
These data indicate that DEX prevents fatal AIH in these mice.
Therapeutic administration of DEX induces regression of inflammation in the liver and significantly increases survival in BALB/c-NTx-PD-1 -/mice
Next, we examined whether corticosteroids might have the same therapeutic efficacy for AIH in BALB/c-NTx-PD-1 -/mice as for human AIH. Because AIH induction was started by 14 days of age in most of the mice, 11, 12 intraperitoneal injections of DEX were started at 17 days ( Figure 1C ). After 6 injections every other day, at four weeks therapeutic injections of DEX suppressed AIH, inducing significantly greater survival ( Figure 1C , D and Supplementary Figure 1B ). These data suggest that similar to human AIH, treatment with corticosteroids after AIH induction is therapeutic for BALB/c-NTx-PD-1 -/mice.
Administration of DEX reduces serum IgG levels and ANA production in BALB/c-NTx-PD-1 -/mice
Using ELISA and immunofluorescence assay, we next examined whether IgG or ANA levels were affected by preventive or therapeutic injections of DEX.
Although serum IgM levels were not changed by DEX treatments, serum IgG levels were significantly reduced by both preventive and therapeutic injections of DEX (Figures 1E) . These data are consistent with the finding in AIH patients, in which reduced serum AST after corticosteroid therapy is generally associated with reduced levels of γ-globulin and of IgG. In addition, ANA levels were reduced significantly in mice with preventive injections and slightly but not significantly in mice receiving therapeutic injections of DEX ( Figures 1E and 1F ).
Therapeutic administration of DEX reduces the size of the spleen but does not completely regress GC-forming B cell follicles and T FH cells in the spleen of BALB/c-NTx-PD-1 -/mice
As reported previously, 12 Figure 2D ). After three days of culture, 7-AADnon-apoptotic cells were significantly and dose-dependently reduced in the CD8 + T-cell population cultured with DEX. In contrast, 7-AADnon-apoptotic cells were not altered in the CD4 + T-cell population cultured with DEX ( Figure 2D ). These data suggest that in BALB/c-NTx-PD-1 -/mice, splenic CD4 + T cells containing T FH cells are more resistant to DEX-mediated apoptosis than effector CD8 + T cells.
Residual splenic CD4 + cells after therapeutic injections of DEX can induce hepatitis in RAG2 -/mice.
Next, we investigated whether residual splenic CD4 + cells after therapeutic DEX injections can induce AIH. Total splenocytes, purified splenic CD4 + cells, or
CD4 + T-cell depleted splenocytes were transferred from BALB/c-NTx-PD-1 -/mice therapeutically treated with DEX at three weeks into T-and B-cell-deficient BALB/c-RAG2 -/mice. Three weeks later, we found that transferring total splenocytes from mice therapeutically treated with DEX induced mononuclear cell infiltrations in the liver of recipient mice and significantly increased serum levels of AST and ALT to levels similar to untreated mice ( Figure 2E and Supplementary Figure 2C ). Notably, purified splenic CD4 + T cells but not CD4 + T-cell-depleted splenocytes also induced hepatitis ( Figure 2F and Supplementary Figure 2D ). Taken together, these data suggest that residual splenic CD4 + cells after DEX injection trigger the recurrence of AIH in mice.
Ending DEX therapy induces fatal hepatitis, whereas extending it allows residual GC-forming B cell follicles in the spleen of BALB/c-NTx-PD-1 -/mice
To examine whether stopping DEX injections results in relapse, DEX administration was ended at 28 days of age after 6 therapeutic injections, or continued until 40 days of age in control mice ( Figure 3A ). Continuous DEX treatment maintained suppressed inflammatory infiltration in the liver and hepatic damage in association with a high survival rate ( Figure 3A , 3B and Supplementary Figure 3 ), but GC-forming B cell follicles were still present in the spleens ( Figure 3B ). In contrast, stopping DEX at 28 days resulted in the recurrence of hepatitis at 40 days, accompanied by reduced survival rates ( Figure 3A , 3B, and Supplementary Figure 3 ). These data suggest a limitation in the therapeutic use of corticosteroids for resolving the dysregulation of T FH cells in the spleen, the AIH-induction site, in BALB/c-NTx-PD-1 -/mice.
Splenectomy after the development of AIH suppresses progression to fatal AIH in BALB/c-NTx-PD-1 -/mice
Previously we reported that neonatal splenectomy has a preventive effect on AIH development in BALB/c-NTx-PD-1 -/mice. 12 In this study, we evaluated splenectomy as a therapeutic option. Similar to the neonatal procedure, splenectomy at 7 or 10 days of age before AIH induction suppressed the development of fatal hepatitis ( Figure 3C ). Importantly, we found that splenectomy at 17 or 21 days of age after AIH development also suppressed liver inflammation and improved survival, sustaining remission until 45 days ( Figure 3C -E).
In addition, splenectomy at 21 days of age following DEX therapy suppressed liver inflammation in association with a high survival rate at 40 days of age, sustaining remission until 60 days ( Figure 3F ). Moreover, when we performed splenectomy at four weeks of age following DEX therapy, liver inflammation was suppressed at 56 days of age ( Supplementary Figure 4) . These data suggest that splenectomy induces prolonged remission of AIH in BALB/c-NTx-PD-1 -/mice.
AIH developed in C57BL/6-NTx-PD-1 -/mice shares characteristic components of chronic hepatitis in AIH patients
In AIH patients, clinical manifestations of AIH are varied, and the disease manifestation has been associated with specific alleles of the major histocompatibility complex. 1-3, 18, 19 To test whether different genetic backgrounds induce milder disease manifestation in NTx-PD-1 -/mice, we performed NTx in PD-1 -/mice that had been backcrossed onto the C57BL/6 background for 11 generations. 20 In two-week-old BALB/c-NTx-PD-1 -/mice with hepatitis, pathogenic splenic T FH cells were preferentially localized within B220 + B-cell follicles and autonomously developed PNA + GCs (Supplementary Figure 5 ). 12 In contrast, although in C57BL/6-NTx-PD-1 -/mice of the same age, splenic CD4 + T cells were located within the follicles, these B-cell follicles did not develop PNA + GCs (Supplementary Figure 5 and Figure These findings are associated with an increased HAI score and increased serum levels of AST and ALT ( Figure 4E and Supplementary Figure 6C ).
In addition, C57BL/6-NTx-PD-1 -/mice older than 4 weeks showed hyper-gammaglobulinemia and significantly increased production of ANAs as detected by ELISA and immunofluorescence assay ( Figure 5A -C). All C57BL/6-NTx-PD-1 -/mice older than 8 weeks developed AIH, whereas some of the AIH-bearing mice, to a lesser frequency, manifested other organ-specific autoimmunity such as sialadenitis, as do patients with chronic AIH ( Figure 5D and Supplementary Table 1 ). [1] [2] [3] These data suggest that human chronic AIH and AIH developed in C57BL/6-NTx-PD-1 -/mice share characteristic components of the disease.
Chronic hepatitis developed in C57BL/6-NTx-PD-1 -/mice is organ-specific autoimmunity induced by CD4 + T cells.
In six-week-old C57BL/6-NTx-PD-1 -/mice, flow cytometric analysis demonstrated that CD3 + T cells predominantly infiltrated the liver. These cells were mainly CD8 + T cells and, to a lesser extent, CD4 + T cells, as described for BALB/c-NTx-PD-1 -/mice ( Figure 5E and 5F). 11 These results were further confirmed by immunohistology ( Figure 6A ). In BALB/c-NTx-PD-1 -/mice, CD4 + T cells in the enlarged spleen directly triggered AIH development. 12 Although adult C57BL/6-NTx-PD-1 -/mice did not show obvious splenomegaly ( Figure 6B and Supplementary Figure 7 ), transfer of splenic CD4 + T cells from AIH-bearing C57BL/6-NTx-PD-1 -/mice at eight weeks of age into T-and B-cell-deficient RAG2 -/mice induced hepatitis in recipient mice at three weeks after transfer ( Figure 6C ). These data suggest that splenic CD4 + T cells directly trigger AIH in this chronic model. In addition, using ELISA sets for cytokines, we found that serum cytokine levels of TNF-α but not IFN-γ increased in six-week-old C57BL/6-NTx-PD-1 -/mice ( Figure 6D ). Furthermore, when we transferred splenic CD4 + T cells from AIH-bearing C57BL/6-NTx-PD-1 -/mice as described above ( Figure 6C ), transferred CD4 + T cells induced not only hepatitis but also elevated serum levels of TNF-α in recipient mice ( Figure 6E ). Because TNF-α directly and indirectly induces cell death of hepatocytes, 21 TNF-α may be involved in hepatocytic damage in C57BL/6-NTx-PD-1 -/mice.
Analysis of the TCR repertoire in several autoimmune diseases has shown antigen-driven clonal expansion of autoreactive T cells in the target organs. [22] [23] [24] [25] [26] In patients with AIH, analyses of the TCR repertoire have shown skewing of V β chain usage, suggesting oligoclonal expansion of liver-infiltrating T cells. 27, 28 In addition, liver-infiltrating LKM-1-specific CD4+ T cell clones have shown a restricted TCR V β repertoire. 29 To determine the clonality of infiltrating CD4 + T cells in the liver, we used In addition, in C57BL/6-NTx-PD-1 -/mice, we found that infiltrates in the liver were less likely to contain Tregs (Supplementary Figure 8A) . Previously, we demonstrated that in BALB/c-NTx-PD-1 -/mice, the transfer of Tregs could not suppress progression of fatal hepatitis after the induction of AIH. 11 However, when
Tregs isolated from splenocytes of adult C57BL/6-PD-1 -/mice (Supplementary Figure   8B ) were transferred into four-week-old C57BL/6-NTx-PD-1 -/mice, the transfer suppressed chronic AIH (Supplementary Figure 8C -E). In humans, Tregs in peripheral blood have the same suppressive activity as Tregs isolated from the spleen in mice. [30] [31] [32] Thus, Tregs isolated from peripheral blood and expanded ex vivo might be able to suppress human AIH. Finally, we evaluated splenectomy as a therapeutic option, performing splenectomies on four-week-old mice. Similar to the neonatal procedure, splenectomy at four weeks suppressed AIH in eight-week-old C57BL/6-NTx-PD-1 -/mice ( Figure   7D , Supplementary Figure 10C and 10D) . Notably, splenectomy neither induced fatal infection nor decreased the survival rate (Supplementary Table 2 ), whereas splenectomy at 12 weeks suppressed AIH, sustaining remission until 20 weeks of age ( Figure 7E and 7F). Thus, these data suggest that splenectomy has therapeutic efficacy for chronic AIH similar to fulminant AIH.
The spleen is the induction site of AIH in C57BL/6-NTx-PD-1
Discussion
Using the AIH models, we here examined the effects of administering dexamethasone (DEX) to find clues to overcoming therapeutic insufficiency of corticosteroids for AIH. We demonstrated that T FH cells in the spleen are responsible not only for the development of AIH but also for relapse after corticosteroid treatment.
In BALB/c-NTx-PD-1 -/mice, the spleen is the induction site for fatal AIH, and responsible T FH cells are dysregulated in the spleen under the concurrent loss of Tregs and PD-1-mediated signaling. CCR6-CCL20 axis-dependent migration of these T cells triggers AIH. 12 In addition, fatal progression is mediated by further differentiation of Th1-type effector T cells from T FH cells in the spleen, and a specific chemokine-dependent migration of those T cells is crucial for fatal progression (unpublished data). We demonstrated that injections of DEX are therapeutic for fatal AIH in this model, whereas T FH cells still exist in the spleen, even after continuous DEX administration: stopping the treatment resulted in fatal AIH. In addition, residual splenic CD4 + T cells after therapeutic injections of DEX were more resistant to DEX-mediated apoptosis, and transfer of these residual splenic CD4 + cells induced the development of hepatitis in the recipient RAG2 -/mice. From these data, we concluded that in the mouse model of AIH, corticosteroid treatment has the drawback of allowing dysregulated T FH cells to remain in the spleen.
We described another In our previous and present studies, we showed that splenectomy, either neonatal or at 7 or 10 days of age before the induction of AIH, suppressed AIH presenting as fulminant hepatic failure in BALB/c-NTx-PD-1 -/mice. 12 In this study, we revealed that neonatal splenectomy also suppressed the development of chronic AIH in C57BL/6-NTx-PD-1 -/mice. Because patients with severe AIH have a high potential for recurrence after liver transplantation, leading to a greater probability of graft loss, splenectomy might well prevent such recurrence.
Interestingly, we further observed in this study that splenectomy after the development of AIH suppressed liver inflammation with manifestations ranging from acute onset to chronic. In the acute AIH model, splenectomy alone suppressed liver inflammation and sustained remission for 4 weeks. In addition, splenectomy following DEX therapy suppressed AIH and extended remission beyond 4 weeks. Moreover, in the chronic AIH model, splenectomy at 12 weeks of age suppressed AIH, sustaining remission until 20 weeks. It is well known that AIH patients in remission after withdrawal of corticosteroids are likely to relapse and that multiple relapses are associated with poor prognosis. 7, 8 Therefore, it is of interest to determine whether, in some patients with AIH, splenectomy might be considered though this will need to be very carefully assessed given the concerns related to splenectomy.
In conclusion, we demonstrated that although corticosteroid treatment has therapeutic efficacy for AIH in mice, it allows residual splenic dysregulated T FH cells to remain after the treatment, which appear to be responsible for relapse. In addition, we found that splenectomy overcomes this insufficiency, inducing prolonged remission of AIH. These data may prove useful in obtaining complete remission in human AIH. 
Figure legends
<Supplementary information>
Supplementary Methods
Mice C57BL/6 and BALB/c mice were purchased from Japan SLC (Shizuoka, Japan), and PD-1 -/and RAG-2 -/mice on a C57BL/6 or BALB/c background were generated as described. [1] [2] [3] All of these mice were bred and housed under specific pathogen-free conditions. Thymectomy and splenectomy of the mice were performed as described. [4] [5] [6] The sham splenectomy was performed by cutting the peritoneum without removing the spleen. All mouse protocols were approved by the Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University.
Administration of dexamethasone (DEX) in vivo
For the preventive protocol, BALB/c-NTx−PD-1 -/mice at one day after thymectomy were intraperitoneally injected every other day with 1.0 mg/kg of DEX (Sigma-Aldrich, St. Louis, MO) diluted in phosphate-buffered saline (PBS) or PBS alone. After 13 injections, mice at four weeks of age were sacrificed, and the livers, spleens, and sera were harvested. For the therapeutic protocol, BALB/c-NTx−PD-1 -/mice at 14 days after thymectomy were intraperitoneally injected every other day with 1.0 mg/kg of DEX diluted in PBS or PBS alone. In C57BL/6-NTx−PD-1 -/mice, the therapeutic injections of 0.5 mg/kg of DEX every other day were started at 4 weeks of age. After indicated injections, mice were sacrificed.
Histological and immunohistological analysis
Organs were fixed in neutral buffered formalin and embedded in paraffin wax. Sections were stained with hematoxylin and eosin or Masson's trichrome for histopathology. Fluorescence immunohistology was performed on frozen sections as described previously 4, 5 using FITC-conjugated anti-CD4 (RM4-5), anti-CD8a (Ly-2) (eBioscience, San Diego, CA), peanut agglutinin (PNA, Vector Laboratories, Burlingame, CA), biotin-labeled anti-B220 (RA3-6B2) (BD Biosciences, San Jose, CA) followed by Texas red-conjugated avidin (Vector Laboratories). To detect autoantibodies, livers were collected from wild-type BALB/c and C57BL/6 mice.
Sections were stained with x100 to x3200 diluted sera from indicated mice, followed by FITC-conjugated anti-mouse IgG (Cappel, Chester, PA). 4
Flow cytometry analysis and isolation of lymphocytes
Single cells from the livers and spleens were prepared as described. 4, 5 The following monoclonal antibodies (mAbs) were used for surface staining: In Foxp3 staining, cells were fixed and permeabilized using Foxp3 staining buffer (eBioscience) and stained with PE-anti-Foxp3 (eBioscience).
ELISA
Serum immunoglobulin (Ig) levels were determined by ELISA as described, 7 and Ab sets to detect mouse IgG1, IgG2a, IgG2b, IgG3 from BD Biosciences and anti-mouse IgM from AbD Serotec (Oxford, UK) were used. To detect serum ANAs, microtiter plates (Nunc, Roskilde, Denmark) were incubated with 10 µg/ml antigens, and the nuclear fraction was prepared from normal liver. 8 Ab sets to detect mouse ANA subclasses were the same as above. Serum concentrations of TNF-α and IFN-γ were measured with mouse cytokine ELISA sets from eBioscience according to the manufacturer's protocols.
Isolation of lymphocytes and adoptive transfer
For transfer of total spleen cells, BALB/c-NTx−PD- 
Histological activity index (HAI) score
Histological activity of chronic active hepatitis was assessed according to a semiquantitative scoring system, as described previously for humans. 9 For histological assessment, all specimens were reviewed blind by at least two hepatologists. Using Knodell's HAI scoring system, liver specimens were graded in 
Supplementary Figure 4
Splenectomy overcomes therapeutic insufficiency of corticosteroids and induces prolonged remission of AIH in BALB/c-NTx-PD-1 -/mice. BALB/c-NTx-PD-1 -/mice at 14 days after thymectomy were intraperitoneally injected every other day with 1.0 mg/kg of DEX. After 6 injections, mice stopped receiving DEX injections and underwent splenectomy (Splx, n=3) or sham operation (n=3) at 28 days of age. Mice at 56 days of age were sacrificed, and the livers were harvested. aminotransferase (AST), and alanine aminotransferase (ALT). (E) Knodell's histological activity index (HAI) score. Bars indicate the mean of each group, and the error bars indicate SD. Asterisks indicate P <0.05. n.s., not significant.
Supplementary Figure 9
Therapeutic injections of DEX suppress chronic AIH in C57BL/6-NTx-PD-1 -/mice. Intraperitoneal injections of DEX (n=5) or PBS (n=5) were started at 4 weeks of age in C57BL/6-NTx-PD-1 -/mice. After 14 injections every other day at eight weeks of age, mice were sacrificed and examined. Serum levels of the liver transaminases AST and ALT are shown. Bars indicate the mean of each group, and the error bars indicate SD. Asterisks indicate P <0.05.
